Immutep Limited IMMP
3.72 USD +0.26 (+7.51%)
Nov 11, 2026, 12:19 PM EST
3.43 Day range 3.74
2.66 52-week range 70.60
- YTD
- +30.07%
- 1 year
- +108.99%
News
benzinga.com Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.
globenewswire.com Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced…
benzinga.com Immutep Reports Encouraging EFTISARC-NEO Phase II Sarcoma Survival Data; Efti + KEYTRUDA + Radiotherapy Shows 81.1% 12-Month DFS, 94.1% LRFS And 86.2% DMFS In 38 Patients First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).With a median…
globenewswire.com Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and…
globenewswire.com IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses SYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune…
globenewswire.com Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026 SYDNEY, AUSTRALIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune…
benzinga.com Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027 Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials…
benzinga.com Immutep Receives Cash Payment Of €1.36M From French Government Under Tax Incentive Program Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash…
benzinga.com Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced health-related quality of life
benzinga.com Immutep Receives A$652,248 Grant From Monash University Under Australian Research Council's Linkage Projects Scheme For Research Collaboration Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce- benzinga.com Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive Program Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash
benzinga.com Immutep Changes ADS Ratio From One ADS Representing 10 Shares To One ADS Representing 200 Shares, Effective September 28 With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Eastern time), the ADS ratio will change from one (1) ADS representing ten (10) ordinary shares to…
benzinga.com Immutep Announces Positive Update For Phase I Trial Evaluation Of Eftilagimod Alfa Key Results from INSIGHT-003 – Data Cutoff – 27 March 2026Approximately 92% of patients enrolled in INSIGHT-003 had no or low PD-L1 expression (Tumour Proportion Score: TPS <50%), representing a…- benzinga.com Immutep To Present Interim Phase I Data For IMP761 At EULAR 2026 First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending dose part of the studyPhase I data demonstrate…
- benzinga.com Immutep Receives Nasdaq Noncompliance Notice, Gets Time Through Oct. 26 To Regain Compliance Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the…
benzinga.com Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbirds up 349%, Snap up 6%. Oil rises 0.7%, gold up 0.1%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles Immutep stock jumps after FDA orphan drug tag for eftilagimod alfa, even as halted Phase 3 trial and mixed analyst views weigh on outlook.
benzinga.com Dow Gains 100 Points; Bank of America Earnings Top Views US stocks up on Wed, Dow +0.22%, NASDAQ +0.37%, S&P 500 +0.28%. Bank of America beats Q1 earnings. Allbirds Inc. shares soar 323%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why NN Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket NN Inc. (NNBR) rose in pre-market trading after announcing expected sales growth and raising full-year guidance. Other gainers include NICM, AGAE, IMMP, LIMN, CIIT, MLSS, LAES, GBR, and STNE. Losers…
benzinga.com Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761 For Autoimmune Diseases Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levelsIMP761 data and Phase I results will be presented at the EULAR…
benzinga.com Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early Immutep announced the discontinuation of the TACTI-004 Phase 3 trial. The CEO expresses disappointment. Stock down 80.62% to $0.53.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com This Karman Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts changed outlook on top names. See ratings page for upgrades, downgrades, and initiations. Analysts recommend H2O, KRMN, GNSS, WCN, and WM stocks.
benzinga.com Crude Oil Gains Over 1%; VEON Shares Spike Higher US stocks mostly lower, Nasdaq drops 0.71%, Dow up 0.03%. Utilities up 1.2%, communication services down 1.2%. PCE index rose 2.8%, GDP up 0.7%.
benzinga.com Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4 U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. U.S. stocks rally as Dow jumps 300+ points on strong morning trading. GDP growth slows in Q4. Energy…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com This EverCommerce Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wall Street analysts change outlook on top companies. See analyst rating changes and their thoughts on EVCM stock before buying.
benzinga.com Baird Downgrades Immutep to Neutral, Lowers Price Target to $1 Baird analyst Joel Beatty downgrades Immutep (NASDAQ:IMMP) from Outperform to Neutral and lowers the price target from $7 to $1.
benzinga.com Why Oncology Institute Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket The Oncology Institute (TOI) stock rose in pre-market trading after reporting better-than-expected financial results. Other gainers include ISPC, PAYP, and EONR.
benzinga.com Citizens Initiates Coverage On Immutep with Market Outperform Rating, Announces Price Target of $10 Citizens analyst Reni J. Benjamin initiates coverage on Immutep (NASDAQ:IMMP) with a Market Outperform rating and announces Price Target of $10.- benzinga.com Citizens Initiates Coverage On Immutep with Market Outperform Rating, Announces Price Target of $6 Citizens analyst Reni J. Benjamin initiates coverage on Immutep (NASDAQ:IMMP) with a Market Outperform rating and announces Price Target of $6.
- benzinga.com Immutep Achieves 50% Participant Enrollment Target In TACTI-004 Phase III Study Evaluating Eftilagimod Alfa In Combination With Merck's Anti-PD-1 Therapy Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient…
benzinga.com Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely Immutep shares update on Phase I study of LAG-3 agonist antibody for autoimmune diseases, showing positive safety & efficacy data.- benzinga.com Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761, LAG-3 Agonist Antibody For Autoimmune Diseases Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels Dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable…
- benzinga.com Immutep Reports Operational Progress In TACTI-004 Phase III Trial Evaluating Eftilagimod Alfa In Combination With MSD's Anti-PD-1 Therapy, KEYTRUDA, And Chemotherapy As First Line Therapy For Advanced/Metastatic Non-Small Cell Lung Cancer The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial's targeted enrolmentStrong operational progress continues globally with over 120 activated clinical…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Immutep Data From EFTISARC-NEO Study Evaluating Eftilagimod Alfa With Radiotherapy Plus KEYTRUDA Exceeds Prespecified Level Of Pathologic Response Rates, Reaches Median 51.5% Tumor Hyalinization/Fibrosis Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the EFTISARC-NEO…
- benzinga.com Immutep Receives ~A$4.6 Million R&D Tax Incentive Payment In Cash From French Government Under Crédit d'Impôt Recherche Scheme Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, is pleased to announce it has received a €2,588,954…
- benzinga.com Immutep Announces U.S. FDA Has Provided Feedback Confirming Successful Completion Of Project Optimus Requirements And Agreement On 30mg As The Optimal Biological Dose For Its Lead Immunotherapy Candidate, Eftilagimod Alfa Confirmation of 30mg efti as optimal biological dose relevant for Immutep's oncology pipeline and potential future Biological License Applications (BLA)Registrational TACTI-004 (KEYNOTE-F91) Phase…
- benzinga.com Immutep Announces Its Global Phase III TACTI-004 Trial For Advanced Non-Small Cell Lung Cancer Has Surpassed Key Milestone With Over 170 Patients Enrolled And Randomized Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysisOver 100 clinical sites across…
- benzinga.com Immutep Initiates Phase II Trial Of Efti As Monotherapy And With Chemotherapy For Early-Stage HR+/HER2- Breast Cancer GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients Second…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- benzinga.com Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session